查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589791

癫痫药物市场：按产品类型、分销管道 - 全球预测 2025-2030

Epilepsy Drug Market by Product Type (First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癫痫药物市值为45.5亿美元，预计到2024年将达到48.7亿美元，复合年增长率为7.09%，到2030年将达到73.5亿美元。

癫痫药物市场包括多种用于控制和治疗癫痫的药物，癫痫是一种以反覆发作为特征的神经系统疾病。这些药物的需求源于控制癫痫发作、尽量减少副作用和改善癫痫患者生活品质的需要。这些治疗剂主要由医院和诊所的医疗保健提供者以及患者本身使用，并构成治疗方法的组成部分。药理学的进步扩大了最终用途的范围，包括学名药和特种药物，以满足各种个人的需求。影响市场开拓的关键因素包括癫痫盛行率的增加、对神经系统疾病的认识不断提高以及药物开发和配方的进步。此外，个人化医疗和生技药品的创新提供了巨大的成长机会。一个值得注意的机会是开发一种疗效较高、副作用较少的药物，以针对对传统治疗有抵抗力的特定类型癫痫。然而，高昂的药物开发成本、严格的监管流程和潜在的副作用等挑战阻碍了市场的成长。此外，专利到期还会带来学名药市场饱和的风险，进而影响盈利。为了应对这些限制，专注于新治疗机制的研究并利用个人化治疗技术（例如使用人工智慧进行基因组分析和药物发现）可能非常有利。鑑于市场竞争激烈且监管严格，与研究机构的策略联盟以及使用真实​​世界的药物功效证据可能会缩短开发时间。投资于医疗保健成本不断上升、未满足的医疗需求不断增加的新兴市场也可以提供强劲的成长轨迹。因此，创新和研究的最佳领域是开发治疗解决方案，解决未满足的需求，提高患者的依从性，并与不断发展的医疗保健政策保持一致，从而支持持续的市场成长。地位。

主要市场统计
基准年[2023] 45.5亿美元
预测年份 [2024] 48.7亿美元
预测年份 [2030] 73.5亿美元
复合年增长率（%） 7.09%

市场动态：快速发展的癫痫药物市场的关键市场洞察

供需的动态交互作用正在改变癫痫药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癫痫患者增加
    • 神经系统疾病、产伤及交通伤害的发生率增加
    • 政府加大投入与支持
  • 市场限制因素
    • 缺乏基础设施和癫痫治疗
  • 市场机会
    • 抗惊厥药物的监管核准增加
    • 联合研究和产品发布活动的渗透
  • 市场挑战
    • 与药物相关的副作用

波特五力：驾驭癫痫药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对癫痫药物市场的影响

外部宏观环境因素在塑造癫痫药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解癫痫药物市场的竞争状况

对癫痫药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癫痫药物市场供应商的绩效评估

FPNV定位矩阵是评估癫痫药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘癫痫药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，癫痫药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癫痫盛行率增加
      • 神经系统疾病、分娩相关伤害和交通事故的发生率增加
      • 政府加大投入与支持
    • 抑制因素
      • 缺乏癫痫基础设施和治疗
    • 机会
      • 抗惊厥药物的监管核准增加
      • 增加协作和产品发布活动
    • 任务
      • 与药物相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癫痫药物市场：依产品类型

  • 第一代医学
    • 乙磺酰亚胺
    • 奥卡西平
    • 苯妥英
  • 第二代医学
    • 非氨酯
    • 拉莫三嗪
    • 托吡酯
  • 第三代医学
    • 醋酸艾斯利卡西平
    • 拉科酰胺
    • 拉非酰胺

第七章 癫痫药物市场：依通路

  • 医院药房
  • 药局

第八章美洲癫痫药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区癫痫药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的癫痫药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Densa Pharmaceuticals Pvt. Ltd.
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Micro Labs Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Psychotropics India Ltd.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB SA
Product Code: MRR-4348D129FAC3

The Epilepsy Drug Market was valued at USD 4.55 billion in 2023, expected to reach USD 4.87 billion in 2024, and is projected to grow at a CAGR of 7.09%, to USD 7.35 billion by 2030.

The epilepsy drug market encompasses a diverse range of medications designed for the management and treatment of epilepsy, a neurological disorder characterized by recurrent seizures. The necessity for these drugs arises from the need to control seizures, minimize side effects, and improve quality of life for epilepsy patients. These medications are primarily utilized by healthcare providers in hospitals, clinics, and by patients themselves, forming an integral part of treatment regimens. Advances in pharmacology have broadened the end-use scope to encompass both generic and specialty drugs catering to various individual needs. Key factors influencing market growth include increased prevalence of epilepsy, heightened awareness about neurological disorders, and advancements in drug development and formulation. Additionally, innovation in personalized medicine and biologics presents significant growth opportunities. One notable opportunity is the development of drugs with improved efficacy and reduced side effects, targeting specific types of epilepsy that are resistant to conventional treatments. However, challenges such as high drug development costs, stringent regulatory processes, and potential side effects hinder market growth. Moreover, patent expirations pose risks of market saturation with generics, impacting profitability. To counter these limitations, focusing on research for new treatment mechanisms and leveraging technology for personalized treatments, such as genomics and AI-driven drug discovery, could be highly advantageous. Given the nature of the market being highly competitive and heavily regulated, strategic alliances with research institutions and leveraging real-world evidence for drug efficacy could accelerate development timelines. Investments in emerging markets with rising healthcare expenditures and unmet medical needs could also provide substantial growth trajectories. Thus, the best areas of innovation and research involve developing therapeutic solutions that address unmet needs, improve patient adherence, and align with evolving healthcare policies, thereby ensuring sustained market growth and leadership.

KEY MARKET STATISTICS
Base Year [2023] USD 4.55 billion
Estimated Year [2024] USD 4.87 billion
Forecast Year [2030] USD 7.35 billion
CAGR (%) 7.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Epilepsy Drug Market

The Epilepsy Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalences of epilepsy
    • Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
    • Rising investment and support from the government
  • Market Restraints
    • Lack of infrastructure and scarcity of treatment for epilepsy
  • Market Opportunities
    • Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • Penetration of collaboration and product launch activities
  • Market Challenges
    • Side effects associated with the drugs

Porter's Five Forces: A Strategic Tool for Navigating the Epilepsy Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Epilepsy Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Epilepsy Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Epilepsy Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Epilepsy Drug Market

A detailed market share analysis in the Epilepsy Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Epilepsy Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Epilepsy Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Epilepsy Drug Market

A strategic analysis of the Epilepsy Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Epilepsy Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Densa Pharmaceuticals Pvt. Ltd., Eisai Co., Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Micro Labs Ltd., Novartis International AG, Pfizer Inc., Psychotropics India Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Epilepsy Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs. The First-Generation Drugs is further studied across Ethosuximide, Oxcarbazepine, and Phenytoin. The Second-Generation Drugs is further studied across Felbamate, Lamotrigine, and Topiramate. The Third-Generation Drugs is further studied across Eslicarbazepine Acetate, Lacosamide, and Ralfinamide.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy and Pharmacy Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalences of epilepsy
      • 5.1.1.2. Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
      • 5.1.1.3. Rising investment and support from the government
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of infrastructure and scarcity of treatment for epilepsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Penetration of collaboration and product launch activities
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Epilepsy Drug Market, by Product Type

  • 6.1. Introduction
  • 6.2. First-Generation Drugs
    • 6.2.1. Ethosuximide
    • 6.2.2. Oxcarbazepine
    • 6.2.3. Phenytoin
  • 6.3. Second-Generation Drugs
    • 6.3.1. Felbamate
    • 6.3.2. Lamotrigine
    • 6.3.3. Topiramate
  • 6.4. Third-Generation Drugs
    • 6.4.1. Eslicarbazepine Acetate
    • 6.4.2. Lacosamide
    • 6.4.3. Ralfinamide

7. Epilepsy Drug Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Pharmacy Stores

8. Americas Epilepsy Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Epilepsy Drug Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Epilepsy Drug Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Densa Pharmaceuticals Pvt. Ltd.
  • 3. Eisai Co., Ltd.
  • 4. GlaxoSmithKline PLC
  • 5. Johnson & Johnson Services, Inc.
  • 6. Micro Labs Ltd.
  • 7. Novartis International AG
  • 8. Pfizer Inc.
  • 9. Psychotropics India Ltd.
  • 10. Sanofi S.A.
  • 11. Sun Pharmaceutical Industries Ltd.
  • 12. Sunovion Pharmaceuticals, Inc.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Torrent Pharmaceuticals Ltd.
  • 15. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. EPILEPSY DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. EPILEPSY DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EPILEPSY DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EPILEPSY DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EPILEPSY DRUG MARKET SIZE, BY OXCARBAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FELBAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EPILEPSY DRUG MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ESLICARBAZEPINE ACETATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LACOSAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL EPILEPSY DRUG MARKET SIZE, BY RALFINAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023